Showing 31-40 of 1908 results for "".
HIPAA Update
https://practicaldermatology.com/topics/practice-management/hipaa-update/19115/Michael J. Sacopulos, JD, Founder and President of Medical Risk Institute talks about recent changes to HIPAA and their possible implications for aesthetic medicine and cosmetic surgery practices. From Vegas Cosmetic Surgery.Atopic Dermatitis: The Critical Need for Treatment
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-the-critical-need-for-treatment/19668/The therapeutic landscape for atopic dermatitis is expanding, as is understanding of the disease and its impact. More than ever, patients need access to effective therapies and meaningful symptom control strategies, says Adam J. Friedman, MD.Psoriasis Update: Understanding the Latest Psoriasis Guidelines
https://practicaldermatology.com/topics/psoriasis/psoriasis-update-understanding-the-latest-psoriasis-guidelines/19777/In a major reversal, the latest psoriasis guidelines recommend against yearly tuberculosis testing for psoriasis patients on biologics who are at low or no risk for TB, says Jashin J. Wu, MD. He also sheds light on studies comparing the 11 biologics that are currently approved for the treatment of pHS Tips and Lizards
https://practicaldermatology.com/programs/practical-dermatology/hs-tips-and-lizards/35858/The latest news and updates, plus a psoriasis update from Jashin J. Wu, MD, FAAD, at Music City SCALE, and Jennifer L. Hsiao, MD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss treating hidradenitis suppurativa and play a game of "Two Truths and a Lie."Introducing SDDS
https://practicaldermatology.com/topics/practice-management/introducing-sdds/19718/Jashin J. Wu, MD, Founder and Course Director, San Diego Dermatology Symposium, introduces a new meeting with topics in acne, psoriasis, pediatric dermatology, cutaneous oncology, and more. UPDATE: The inaugural 2020 San Diego Dermatology Symposium will be held September 11-13, 2020 at the InterConPsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Dermatology and CTCL: Recommendations
https://practicaldermatology.com/series/dermwire-tv/dermatology-and-ctcl-recommendations/26798/Larisa J. Geskin, MD, Professor of Dermatology at Columbia University Medical Center, discusses "Time to Act: A Global Patient-Focused Consensus for Improving Care in Cutaneous T-Cell Lymphoma (CTCL)," a global consensus statement from Kyowa Kirin that recommends, among other things, that dermatologQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andCOVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditiAdvocating for Dermatology
https://practicaldermatology.com/topics/practice-management/advocating-for-dermatology/18578/Host Neal Bhatia, MD sits down with two dermatologists with a great deal of experience advocating for the field — Terrence A. Cronin Jr, MD and Lawrence J. Green, MD. They share insights into how advocacy arms like SkinPAC and the Advisory Board committee of the American Academy of Dermatology work.